TFE3 and renal cell carcinoma: Including 8 cases of ASPSCR1-TFE3 RCC, 8 cases of PRCC-TFE3 RCC and the 13 cases of fusion partner undefined Xp11.2 translocation RCC, NONO-TFE3 RCC in our study accounted for 17.2% of the total population of Xp11.2 translocation RCC patients.